Contents
Special Issue Topic

Off-Label Drugs and -Omics Data in Cancer Treatment

Guest Editors

Dr. Luca Agnelli E-Mail

Department of Oncology and Hemato-oncology, University of Milan, Milan, Italy

Research Keywords: lymphoid malignancies; bioinformatics and biostatistics in cancer; -omics analyses; NGS; non-coding RNA

Dr. Giancarlo Pruneri E-Mail

Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy

About the Special lssue

The knowledge about cancer has improved on the basis of -omics studies. The integration of genetic information about cancers with data on how the cancers respond to target based-therapy help to define optimum cancer treatment. As a consequence, in the last decades, targeted therapies led to unprecedented clinical benefit in first-line therapies, as well as in patients with aggressive or advanced neoplasms bearing specific genomic alterations (gene mutations, amplifications, translocations, microsatellite instability). Although it would be desirable to increase the number of clinical trials and standardized treatments, several factors influence so far the choice of therapies, including the non-trivial aspect of the cost-effective manageability by the Healthcare National Institutions. For this reason, several non-standard treatments are commonly considered, and off-label drug usage is a common practice in treating cancer, in most cases based on physician choice. This common clinical practice suffers from a lack of knowledge base for proper cancer drug selections. The present issue is aimed at focusing on all the aspects (clinical evidence, procedures, scientific hypothesis, and investigations) involving off-label drugs for cancer treatment in the context of -omics data.

Keywords: Off-label drugs; omics data; real-world cancer treatments; (targeted) NGS; biomarkers

Published Articles

Open Access Review
Overcoming phenotypic switching: targeting protein-protein interactions in cancer
Christos Ladias ... Nikolaos A. Papanikolaou
Published: October 30, 2023 Explor Target Antitumor Ther. 2023;4:1071–1081
2183 28 1
Open Access Original Article
Targeted RNA-sequencing analysis for fusion transcripts detection in tumor diagnostics: assessment of bioinformatic tools reliability in FFPE samples
Iolanda Capone ... Giancarlo Pruneri
Published: October 27, 2022 Explor Target Antitumor Ther. 2022;3:582–597
1970 26 3
Open Access Review
A personalized molecular approach in multiple myeloma: the possible use of RAF/RAS/MEK/ERK and BCL-2 inhibitors
Vincenzo Raimondi ... Nicola Giuliani
Published: August 31, 2022 Explor Target Antitumor Ther. 2022;3:463–479
3242 43 6
Open Access Review
The evolving role and utility of off-label drug use in multiple myeloma
James H Stoeckle ... Gareth J Morgan
Published: August 30, 2021 Explor Target Antitumor Ther. 2021;2:355–373
5487 48 1
Open Access Review
Multi-omics tumor profiling technologies to develop precision medicine in multiple myeloma
Sara Ovejero, Jerome Moreaux
Published: February 28, 2021 Explor Target Antitumor Ther. 2021;2:65–106
4899 65 1